Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron (NASDAQ: LGVN) announced the appointment of Ursula Ungaro to its Board of Directors, effective June 1, 2021. Ungaro, who has served on the U.S. District Court for the Southern District of Florida since 1992, brings extensive legal experience, particularly in civil and securities law. Her retirement from the judiciary was motivated by her desire to contribute to Longeveron's growth in cellular therapies, including the development of Lomecel-B for aging-related conditions. CEO Geoff Green expressed confidence in her ability to guide the company's clinical advancements and commercialization efforts.
Longeveron Inc. (NASDAQ: LGVN) has appointed Dan Gincel, Ph.D., as Senior Vice President of Strategic Collaborations & Scientific Affairs. Gincel brings over 20 years of experience in regenerative medicine, including leadership roles in public-private partnerships. Previously, he managed over $150 million in funding while at the Maryland Stem Cell Research Fund. CEO Geoff Green noted Gincel's expertise will help advance Longeveron's mission to develop cell therapies for aging-related diseases. The company is currently conducting Phase 1 and 2 clinical trials for multiple conditions.
Longeveron Inc. (NASDAQ: LGVN) provided a business update and Q1 financial results as of March 31, 2021. The company is developing allogeneic cell therapies targeting chronic aging-related diseases, including Alzheimer's. Notably, the Phase 1 Alzheimer’s study showed Lomecel-B to be well tolerated with no serious adverse events and evidence of slowing cognitive decline. Longeveron plans to initiate a Phase 2 study in the second half of the year and expects to announce top-line results from Phase 2 Aging Frailty trials in Q3. The upcoming presentations at significant conferences highlight the company's ongoing research.
Longeveron Inc. (NASDAQ: LGVN) announced it will release its first quarter 2021 financial results on May 14, 2021, before US market open. Management will host a conference call at 8:30 AM that day. The company focuses on cellular therapies for aging-related and life-threatening conditions, with its lead product, LOMECEL-B™, undergoing Phase 1 and 2 clinical trials for various serious conditions, including Aging Frailty and Alzheimer's disease. The aim is to advance therapies into pivotal Phase 3 trials for regulatory approval and commercialization.
Longeveron announced positive Phase 1 study results of Lomecel-B for treating Alzheimer's disease and completed two Phase 2 trials evaluating its safety and efficacy in Aging Frailty subjects. Top-line results from these studies are expected in Q3 2021. The CEO, Geoff Green, will present at the Benzinga Global Small Cap Conference on May 13-14, 2021, highlighting the company's clinical research efforts, including aging-related conditions. Longeveron aims to advance Lomecel-B towards regulatory approval and commercialization.
Longeveron Inc. (NASDAQ: LGVN) has been selected to present at the 2021 World Stem Cell Summit from June 14-18. Dr. Joshua Hare, Chief Science Officer, will discuss the Longevity Agenda and present findings on Lomecel-B, a therapy targeting aging-related conditions like Alzheimer's and Aging Frailty. The company anticipates sharing results from clinical trials in the third quarter. Geoff Green, CEO, expressed pride in participating in this prestigious event, emphasizing the promise of cell-based therapies in improving healthspan.
Longeveron has completed a Phase I/II clinical study evaluating Lomecel-B's effectiveness in enhancing immune response to the flu vaccine in elderly individuals with aging frailty. Funded partially by the Maryland Technology Development Corporation and the National Institute on Aging, the study involved randomized, double-blinded trials at seven centers in Florida and Maryland. Results are expected in Q3 2021, revealing Lomecel-B's potential to mitigate inflammation and improve B cell function for better vaccine response in this vulnerable population.
Longeveron Inc. (NASDAQ: LGVN) announced positive final results from its Phase 1 clinical trial of Lomecel-B for treating mild Alzheimer’s disease. The study met its primary safety endpoint and showed that cognitive decline was slower in patients receiving low-dose Lomecel-B compared to placebo. Notably, quality of life metrics improved, with significant differences at 26 weeks. Complete trial results will be published soon. The company is poised to initiate a Phase 2 study in the latter half of 2021, indicating a proactive approach towards potential Alzheimer's treatments.
Longeveron Inc. (NASDAQ: LGVN) reported its financial results for Q4 and full year 2020, highlighting a net loss of $1.4 million for Q4 compared to $0.5 million in Q4 2019. Revenue was $1.2 million in Q4 2020, down from $1.8 million in Q4 2019, primarily due to decreased grant revenue. However, revenue from the Bahamas Registry Trial increased by 119% year-over-year. The company secured a $29.1 million IPO and anticipates sufficient cash to support operations through Q4 2022. Upcoming results from multiple clinical trials are expected in 2021.
Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company, announced a conference call on March 30, 2021, at 8:30 a.m. ET to discuss its fiscal 2020 financial results and provide a business update. The call will be accessible via telephone and a webcast. Longeveron is focused on developing cellular therapies for chronic aging-related and life-threatening conditions, with its lead product, LOMECEL-B™, targeting multiple indications including Aging Frailty and Alzheimer’s disease. An audio replay of the call will be available until April 6, 2021.